Emerging Strategies in TCR-Engineered T Cells
Immunotherapy of cancer has made tremendous progress in recent years, as demonstrated by the remarkable clinical responses obtained from adoptive cell transfer (ACT) of patient-derived tumor infiltrating lymphocytes, chimeric antigen receptor (CAR)-modified T cells (CAR-T) and T cell receptor (TCR)-...
Main Authors: | Fang Wei, Xiao-Xia Cheng, John Zhao Xue, Shao-An Xue |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.850358/full |
Similar Items
-
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
by: Francesco Manfredi, et al.
Published: (2020-09-01) -
The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses
by: Diana Campillo-Davo, et al.
Published: (2020-07-01) -
TCR engineered T cells for solid tumor immunotherapy
by: Yikai Zhang, et al.
Published: (2022-06-01) -
The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering
by: D. V. Shevyrev, et al.
Published: (2022-11-01) -
Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells
by: Guido J.J. Kierkels, et al.
Published: (2021-09-01)